Just a moment, the page is loading...
Browse ALL STUDIES
Keyword Search
View All Selected
Clear All
Login / Create Account
Login
Create Account
Home
About Us
Privacy Policy
Minimum System Requirements
How To Join
Mission
Data Sponsors
Researchers
How It Works
How to Request Data
Review of Requests
Data Sharing Agreement
Access to Data
Independent Review Panel
Metrics
FAQs
News
Help/Contact Us
Evaluation of Postmastectomy Radiotherapy in Women with HER-2 positive Breast Cancer
Proposal
5453
Title of Proposed Research
Evaluation of Postmastectomy Radiotherapy in Women with HER-2 positive Breast Cancer
Lead Researcher
Youssef Zeidan
Affiliation
American University of Beirut, Medical Center
Funding Source
Potential Conflicts of Interest
Data Sharing Agreement Date
29 August 2018
Lay Summary
Although previous research showed improved survival and loco-regional control for breast cancer patients undergoing post mastectomy radiation therapy (PMRT) [1-3], the applicability of such results in patients with HER 2 positive tumors remains unknown. These trials preceded, the introduction of HER 2 targeted therapy, mainly Trastuzumab. In addition, the use of PMRT in patients with pT1-pT2 tumors and 1-3 positive lymph nodes remains controversial. Hence, analyzing the effect of PMRT in patients with positive HER 2 status could potentially help fine tune treatment recommendations.
Study Data Provided
[{ "PostingID": 5066, "Title": "ROCHE-BO16348", "Description": "A Randomized Three-Arm, Multicenter Comparison of 1 Year and 2 Years of Herceptin Versus No Herceptin in Women With HER2-Positive Primary Breast Cancer Who Have Completed Adjuvant Chemotherapy" }]
Statistical Analysis Plan
Statistical Strategy: Performed by Hani Tamim (PhD in Epidemiology and Biostatistics) and Aurelie Mailhac (MS in Epidemiology and Biostatistics)1. Power CalculationThe planned study is a secondary data analysis, which entails a predetermined sample size. Based on the published numbers in the primary study on this cohort [11] the estimated numbers of participants with mastectomy in the PMRT(+) and PMRT(-) are of 1214 and 724, respectively. We estimated the LRR proportion in the unexposed group to be of 15%. With an expected 5% reduction in the exposed group (LRR proportion = 10%) and an alpha of 5%, the power calculation yielded 80%. Larger reductions will yield higher power.For the subgroup analyses (HER-2 positive, pT1-pT2 tumors, post-mastectomy, on Trastuzumab) with the estimated numbers of 364 participants in the exposed group and 217 in the unexposed group, an LRR proportion of 10% among the non-exposed, a reduction of 6% in the exposed (LRR proportion = 4%) and an alpha of 5%, the power calculation yielded 75.4%.2. Statistical AnalysisUnivariate analyses will be conducted to describe the cohort. Categorical variables will be presented as frequencies and percent, and continuous variables as means and standard deviations (SD). Bivariate analyses will be used to compare characteristics as well as outcomes in frequencies and percent between exposed PMRT(+) and unexposed PMRT(-) groups, using the independent t-test (continuous variables) or the chi-square test (categorical variables). Multivariate regression analyses will be used to evaluate the association between radiation and LRR while adjusting for potentially confounding variables. Moreover, results will be presented as odds ratios (OR) with their associated 95% confidence intervals (95% CI). Factors considered for inclusion in the multivariate analyses will depending on the statistical significance of the bivariate analyses, as well as the clinical significance of different characteristics. Moreover, Kaplan Meier curves will be constructed to describe the time to recurrence in both radiation groups. Furthermore, to adjust for the confounding variables, while considering time to recurrence as an outcome, Cox proportional hazards regression modeling will be used to estimate the Hazard Ratios (HR) with 95% CI. Statistical significance will be set at an alpha of 5% for a two-sided p-value. Analyses will be conducted using SAS 9.4.
Publication Citation
Abi Jaoude J, de Azambuja E, Makki M, et al. Post-Mastectomy Radiation Therapy in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer Patients: Analysis of the HERA Trial. Int J Radiat Oncol Biol Phys. 2020;106(3):503-510. doi:10.1016/j.ijrobp.2019.10.022
© 2024 ideaPoint. All Rights Reserved.
Powered by ideaPoint.
Help
Privacy Policy
Cookie Policy
Help and Resources